Accretropin (somatropin rDNA Original)

Company
Cangene

Approval Status
Approved January 2008

Treatment for
growth failure in pediatrics

Areas
Diabetes / Endocrinology , Pediatrics

Accretropin is a sustained release formulation of recombinant human growth hormone product. This protein is produced by recombinant DNA technology during fermentation in E. coli, yielding a protein containing 192 amino acids. The N-terminal amino acid, methionine, is later removed to yield a protein that is chemically and physicochemically identical to pituitary derived human growth hormone, consisting of 191 amino acids in a single polypeptide chain.

Accretropin is specifically indicated for the treatment of pediatric patients who have growth failure due to an inadequate secretion of normal endogenous growth hormone and for the treatment of short stature associated with Turner Syndrome in pediatric patients whose epiphyses are not closed.

Accretropin is supplied as a solution designed for subcutaneous administration. The recommended initial dose of the drug is as follows:
Growth Hormone Deficiency
The recommended weekly dose is 0.18 mg/kg body weight to 0.3 mg/kg (0.90 IU/kg) body weight. The dose should be divided into equal daily doses given 6 or 7 times per week subcutaneously.
Turner Syndrome
The recommended weekly dose is 0.36 mg/kg of body weight. The dose should be divided into equal daily doses given 6 or 7 times per week subcutaneously.

Failure of Accretropin to increase growth rate, particularly during the first year of therapy, should prompt assessment of compliance and evaluation of other causes of growth failure such as hypothyroidism, under-nutrition and advanced bone age.

FDA Approval
FDA approval of Accretropin was based on the results of two clinical trials.

Growth Hormone Deficiency
This single-arm, open-label, multicenter trial enrolled 44 pediatric subjects who were treated for up to 3 years with an Accretropin dose of 0.03 to 0.05 mg/kg/day (0.18 to 0.30 mg/kg/week) subcutaneously. Height SD score calculated relative to population of normally growing children increased on Accretropin treatment from -3.04 at baseline to -2.46 at one year, -2.12 at two years, and -1.78 at three years.

Turner Syndrome
This single-arm, open-label, single-center trial enrolled 37 subjects who received an Accretropin dose of 0.06 mg/kg/day subcutaneously (0.36 mg/kg/week). Height SD score calculated relative to population of Turner Syndrome patients increased on Accretropin treatment from -3.17 at baseline to -2.67 at one year, -2.43 at two years, and -2.28 at three years.

Adverse events associated with the use of Accretropin for growth hormone deficiency may include, but are not limited to, the following:

  • injection site reactions
  • nausea
  • headache
  • fatigue
  • scoliosis

Adverse events associated with the use of Accretropin for Turner Syndrome may include, but are not limited to, the following:

  • injection site reactions, including erythema, edema, pain, pruritis

Accretropin is a sustained release formulation of recombinant human growth hormone product. This protein is produced by recombinant DNA technology during fermentation in E. coli, yielding a protein containing 192 amino acids. The N-terminal amino acid, methionine, is later removed to yield a protein that is chemically and physicochemically identical to pituitary derived human growth hormone, consisting of 191 amino acids in a single polypeptide chain.

For additional information regarding Accretropin or short stature in pediatrics due to growth hormone deficiencies or Turner Syndrome, please visit the Accretropin webpage.

Accretropin (somatropin rDNA Original) Drug Information

The Accretropin (somatropin rDNA Original) drug information shown above is licensed from Thomson CenterWatch. The information provided here is for general educational purposes only and does not constitute medical or pharmaceutical advice which should be sought from qualified medical and pharmaceutical advisers.

Scroll to top